{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:51:32Z","timestamp":1790736692457,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T00:00:00Z","timestamp":1480032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent study showed periostin play a pivotal role in abnormal liver triglyceride (TG) accumulation and in the development of obesity-related liver fat accumulation. However, little is known regarding whether periostin plays a key role in the heightened prevalence of NAFLD and other metabolic phenotypes among large-scale populations. A cross-sectional sample of 8850 subjects aged 40\u2009yr or older from China were evaluated in this study. Serum periostin was measured by ELISA methods. The diagnosis of NAFLD by liver ultrasonic examination. Among overweight and obese subjects, NAFLD subjects had higher serum periostin levels than those without NAFLD (126.75\u2009ng\/ml vs. 75.96\u2009ng\/ml, p\u2009&lt;\u20090.001). Periostin was associated with a higher risk for NAFLD (OR 1.75 for each SD increase in periostin, 95% CI 1.04\u20133.37, p\u2009&lt;\u20090.001) among overweight and obese subjects after confounder adjustment. Furthermore, periostin levels among overweight and obese subjects were correlated with aspartate aminotransferase (r\u2009=\u20090.102, p\u2009=\u20090.004), alanine aminotransferase (r\u2009=\u20090.108, p\u2009=\u20090.003), waist circumference (r\u2009=\u20090.111, p\u2009=\u20090.002), homeostasis model assessment index-insulin resistance (r\u2009=\u20090.154, p\u2009&lt;\u20090.001) and fasting plasma insulin (r\u2009=\u20090.098, p\u2009=\u20090.006), TG (r\u2009=\u20090.117, p\u2009=\u20090.001). Elevated circulating periostin level was associated with an increased risk of having NAFLD and insulin resistance among overweight and obese individuals.<\/jats:p>","DOI":"10.1038\/srep37886","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T10:04:24Z","timestamp":1480068264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects"],"prefix":"10.1038","volume":"6","author":[{"given":"Zhen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"BFsrep37886_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee, Q. M. et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10, 330\u201344 (2013).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"BFsrep37886_CR2","doi-asserted-by":"publisher","first-page":"d3897","DOI":"10.1136\/bmj.d3897","volume":"343","author":"QM Anstee","year":"2011","unstructured":"Anstee, Q. M. et al. How big a problem is non-alcoholic fatty liver disease? BM J 343, d3897 (2011).","journal-title":"BM J"},{"key":"BFsrep37886_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen, J. C. et al. Human fatty liver disease: old questions and new insights. Science 332, 1519\u201323 (2011).","journal-title":"Science"},{"key":"BFsrep37886_CR4","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.3390\/nu7064995","volume":"7","author":"E Fabbrini","year":"2015","unstructured":"Fabbrini, E. et al. Hepatic steatosis as a marker of metabolic dysfunction. Nutrients 7, 4995\u20135019 (2015).","journal-title":"Nutrients"},{"key":"BFsrep37886_CR5","doi-asserted-by":"publisher","first-page":"11131","DOI":"10.1128\/MCB.25.24.11131-11144.2005","volume":"25","author":"H Rios","year":"2005","unstructured":"Rios, H. et al. Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25, 11131\u201344 (2005).","journal-title":"Mol Cell Biol"},{"key":"BFsrep37886_CR6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00198-011-1892-7","volume":"23","author":"B Merle","year":"2012","unstructured":"Merle, B. & Garnero, P. The multiple facets of periostin in bone metabolism. Osteoporos Int 23, 1199\u2013212 (2012).","journal-title":"Osteoporos Int"},{"key":"BFsrep37886_CR7","doi-asserted-by":"publisher","first-page":"E1014","DOI":"10.1210\/jc.2015-1183","volume":"100","author":"N Bonnet","year":"2015","unstructured":"Bonnet, N. et al. Additive genetic effects on circulating periostin contribute to the heritability of bone microstructure. J Clin Endocrinol Metab 100, E1014\u201321 (2015).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep37886_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1535-6108(04)00081-9","volume":"5","author":"S Bao","year":"2004","unstructured":"Bao, S. et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt\/PKB pathway. Cancer Cell 5, 329\u201339 (2004).","journal-title":"Cancer Cell"},{"key":"BFsrep37886_CR9","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1172\/JCI74438","volume":"124","author":"Y Lu","year":"2014","unstructured":"Lu, Y. et al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPAR\u03b1. J Clin Invest 124, 3501\u201313 (2014).","journal-title":"J Clin Invest"},{"key":"BFsrep37886_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cmet.2014.09.005","volume":"20","author":"T Wu","year":"2014","unstructured":"Wu, T. et al. Periostin: a new extracellular regulator of obesity-induced hepatosteatosis. Cell Metab 20, 562\u20134 (2014).","journal-title":"Cell Metab"},{"key":"BFsrep37886_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jhep.2014.10.005","volume":"62","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis. J Hepatol 62, 495\u20137 (2015).","journal-title":"J Hepatol"},{"key":"BFsrep37886_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","volume":"5","author":"MK Badman","year":"2007","unstructured":"Badman, M. K. et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5, 426\u201337 (2007).","journal-title":"Cell Metab"},{"key":"BFsrep37886_CR13","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1210\/jc.2008-1505","volume":"93","author":"T Reinehr","year":"2008","unstructured":"Reinehr, T. et al. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 93, 4479\u201385 (2008).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep37886_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2012.258","volume":"9","author":"N Stefan","year":"2013","unstructured":"Stefan, N. et al. The role of hepatokines in metabolism. Nat Rev Endocrinol 9, 144\u201352 (2013).","journal-title":"Nat Rev Endocrinol"},{"key":"BFsrep37886_CR15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/en.2014-1637","volume":"156","author":"JK Smid","year":"2015","unstructured":"Smid, J. K. et al. Periostin induces pancreatic regeneration. Endocrinology 156, 824\u201336 (2015).","journal-title":"Endocrinology"},{"key":"BFsrep37886_CR16","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. et al. NAFLD: a multisystem disease. J Hepatol 62, S47\u201364 (2015).","journal-title":"J Hepatol"},{"key":"BFsrep37886_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cmet.2014.05.001","volume":"20","author":"A Umemura","year":"2014","unstructured":"Umemura, A. et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 20, 133\u201344 (2014).","journal-title":"Cell Metab"},{"key":"BFsrep37886_CR18","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1001\/jama.289.22.3000","volume":"289","author":"JM Clark","year":"2003","unstructured":"Clark, J. M. et al. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 289, 3000\u20134 (2003).","journal-title":"JAMA"},{"key":"BFsrep37886_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cmet.2006.06.008","volume":"4","author":"K Uyeda","year":"2006","unstructured":"Uyeda, K. et al. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4, 107\u201310 (2006).","journal-title":"Cell Metab"},{"key":"BFsrep37886_CR20","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI41636","volume":"122","author":"F Benhamed","year":"2012","unstructured":"Benhamed, F. et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 122, 2176\u201394 (2012).","journal-title":"J Clin Invest"},{"key":"BFsrep37886_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1753-0407.2012.00182.x","volume":"4","author":"G Ning","year":"2012","unstructured":"Ning, G. et al. Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal (REACTION) study. J Diabetes 4, 172\u20133 (2012).","journal-title":"J Diabetes"},{"key":"BFsrep37886_CR22","first-page":"83","volume":"15","author":"BF Zhou","year":"2002","unstructured":"Zhou, B. F. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults\u2013study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 15, 83\u201396 (2002).","journal-title":"Biomed Environ Sci"},{"key":"BFsrep37886_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u20139 (1985).","journal-title":"Diabetologia"},{"key":"BFsrep37886_CR24","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","volume":"17","author":"YC Ma","year":"2006","unstructured":"Ma, Y. C. et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17, 2937\u201344 (2006).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep37886_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","volume":"50","author":"JG Fan","year":"2009","unstructured":"Fan, J. G. et al. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50, 204\u201310 (2009).","journal-title":"J Hepatol"},{"key":"BFsrep37886_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.20734","volume":"42","author":"G Bedogni","year":"2005","unstructured":"Bedogni, G. et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42, 44\u201352 (2005).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep37886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37886","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:46:08Z","timestamp":1672886768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep37886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep37886"],"URL":"https:\/\/doi.org\/10.1038\/srep37886","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]},"assertion":[{"value":"20 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37886"}}